National-, institutional-, and individual-level determinants of
pharmacology and pharmacy research excellence: an analysis of
stanford-elsevier lists of the top 2% scholars (2017-2023)

J 2026

National-, institutional-, and individual-level determinants of pharmacology and pharmacy research excellence: an analysis of stanford-elsevier lists of the top 2% scholars (2017-2023)

RIAD, Abanoub; Lenka SOUČKOVÁ; Jitka RYCHLÍČKOVÁ a Michal KOŠČÍK

Základní údaje

Originální název

National-, institutional-, and individual-level determinants of pharmacology and pharmacy research excellence: an analysis of stanford-elsevier lists of the top 2% scholars (2017-2023)

Autoři

RIAD, Abanoub; Lenka SOUČKOVÁ; Jitka RYCHLÍČKOVÁ a Michal KOŠČÍK

Vydání

Naunyn-Schmiedebergs Archives of Pharmacology, New York, Springer, 2026, 0028-1298

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.100 v roce 2024

Označené pro přenos do RIV

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Academies and institutes; Bibliometrics; Macroeconomics; Meta-research; Pharmaceutical research; Research personnel

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 25. 2. 2026 10:33, Mgr. Tereza Miškechová

Anotace

V originále

Researchexcellence in pharmacology and pharmacy remains insufficiently studied compared with broader analyses of productivity, despite its centrality to advancing drug discovery and health outcomes. This study investigated the multilevel determinants of pharmacology and pharmacy research excellence, defined by membership in the Stanford-Elsevier Top 2% Scientists Lists (SEL). We analyzed 56,358 records in SELs between 2017 and 2023 using a multilevel socio-ecological model. Independent variables spanned national determinants (e.g., health system capacity, human development, gender inequality, R&D investment), institutional factors (global and field-specific rankings), and individual characteristics (gender and academic age). Core bibliometric outcomes included citation counts excluding self-citations, modified H-index, and composite scores. Excellence was disproportionately concentrated in high-income countries and a limited number of elite institutions, although contributions from middle-income countries expanded over time. National R&D investment, Universal Health Coverage, and Human Development Index values consistently predicted higher bibliometric outcomes, while gender inequality was negatively associated with excellence. Disease burdens mirrored these inequities: conditions common in high-income settings (e.g., cancers, COPD) correlated positively with excellence, whereas major global burdens (e.g., HIV/AIDS, diabetes) correlated negatively. Institutional concentration illustrated the Matthew effect, with the top 20 institutions accounting for over one-tenth of global excellence. At the individual level, female scholars remained underrepresented (16.8% in career-long, 25.0% in single-year lists) and showed lower bibliometric performance and younger academic ages than men. Academic age emerged as the strongest positive predictor of research impact, with consistent gains across both datasets. Pharmacology and pharmacy research excellence is conditioned by systemic disparities in resources, prestige, and representation. Policy interventions must target these entrenched capacity-based advantages by strengthening research capacity in underrepresented countries and institutions and implementing frameworks for gender-equitable career progression.

Návaznosti

LX22NPO5101, projekt VaV

Název: Národní institut pro výzkum socioekonomických dopadů nemocí a systémových rizik (Akronym: SYRI)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Národní institut pro výzkum socioekonomických dopadů nemocí a systémových rizik, 5.1 EXCELES

NW26J-09-00120, projekt VaV

Název: Zlepšení bezpečnosti vakcín prostřednictvím klinicky orientované klasifikace nežádoucích účinků a behaviorální analýzy hlášení (COVARE)

Investor: Ministerstvo zdravotnictví ČR, Zlepšení bezpečnosti vakcín prostřednictvím klinicky orientované klasifikace nežádoucích účinků a behaviorální analýzy hlášení (COVARE), Podprogram 2 - juniorský

Citovat

RIAD, Abanoub; Lenka SOUČKOVÁ; Jitka RYCHLÍČKOVÁ a Michal KOŠČÍK. National-, institutional-, and individual-level determinants of pharmacology and pharmacy research excellence: an analysis of stanford-elsevier lists of the top 2% scholars (2017-2023). Naunyn-Schmiedebergs Archives of Pharmacology. New York: Springer, 2026, 33 s. ISSN 0028-1298. Dostupné z: https://doi.org/10.1007/s00210-025-04949-4.

@article{2556637,
   author = {Riad, Abanoub and Součková, Lenka and Rychlíčková, Jitka and Koščík, Michal},
   article_location = {New York},
   doi = {https://doi.org/10.1007/s00210-025-04949-4},
   keywords = {Academies and institutes; Bibliometrics; Macroeconomics; Meta-research; Pharmaceutical research; Research personnel},
   language = {eng},
   issn = {0028-1298},
   journal = {Naunyn-Schmiedebergs Archives of Pharmacology},
   title = {National-, institutional-, and individual-level determinants of pharmacology and pharmacy research excellence: an analysis of stanford-elsevier lists of the top 2% scholars (2017-2023)},
   url = {https://link.springer.com/article/10.1007/s00210-025-04949-4},
   year = {2026}
}

TY  - JOUR
ID  - 2556637
AU  - Riad, Abanoub - Součková, Lenka - Rychlíčková, Jitka - Koščík, Michal
PY  - 2026
TI  - National-, institutional-, and individual-level determinants of pharmacology and pharmacy research excellence: an analysis of stanford-elsevier lists of the top 2% scholars (2017-2023)
JF  - Naunyn-Schmiedebergs Archives of Pharmacology
PB  - Springer
SN  - 00281298
KW  - Academies and institutes
KW  - Bibliometrics
KW  - Macroeconomics
KW  - Meta-research
KW  - Pharmaceutical research
KW  - Research personnel
UR  - https://link.springer.com/article/10.1007/s00210-025-04949-4
N2  - Researchexcellence in pharmacology and pharmacy remains insufficiently studied compared with broader analyses of productivity, despite its centrality to advancing drug discovery and health outcomes. This study investigated the multilevel determinants of pharmacology and pharmacy research excellence, defined by membership in the Stanford-Elsevier Top 2% Scientists Lists (SEL). We analyzed 56,358 records in SELs between 2017 and 2023 using a multilevel socio-ecological model. Independent variables spanned national determinants (e.g., health system capacity, human development, gender inequality, R&D investment), institutional factors (global and field-specific rankings), and individual characteristics (gender and academic age). Core bibliometric outcomes included citation counts excluding self-citations, modified H-index, and composite scores. Excellence was disproportionately concentrated in high-income countries and a limited number of elite institutions, although contributions from middle-income countries expanded over time. National R&D investment, Universal Health Coverage, and Human Development Index values consistently predicted higher bibliometric outcomes, while gender inequality was negatively associated with excellence. Disease burdens mirrored these inequities: conditions common in high-income settings (e.g., cancers, COPD) correlated positively with excellence, whereas major global burdens (e.g., HIV/AIDS, diabetes) correlated negatively. Institutional concentration illustrated the Matthew effect, with the top 20 institutions accounting for over one-tenth of global excellence. At the individual level, female scholars remained underrepresented (16.8% in career-long, 25.0% in single-year lists) and showed lower bibliometric performance and younger academic ages than men. Academic age emerged as the strongest positive predictor of research impact, with consistent gains across both datasets. Pharmacology and pharmacy research excellence is conditioned by systemic disparities in resources, prestige, and representation. Policy interventions must target these entrenched capacity-based advantages by strengthening research capacity in underrepresented countries and institutions and implementing frameworks for gender-equitable career progression.
ER  -

RIAD, Abanoub; Lenka SOUČKOVÁ; Jitka RYCHLÍČKOVÁ a Michal KOŠČÍK. National-, institutional-, and individual-level determinants of pharmacology and pharmacy research excellence: an analysis of stanford-elsevier lists of the top 2\%{} scholars (2017-2023). \textit{Naunyn-Schmiedebergs Archives of Pharmacology}. New York: Springer, 2026, 33 s. ISSN~0028-1298. Dostupné z: https://doi.org/10.1007/s00210-025-04949-4.

Přehled o publikaci